Premium
Designing In and Around Tolerability Considerations for Immunotherapy Combinations
Author(s) -
Stroh Mark
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.945
Subject(s) - tolerability , immunotherapy , medicine , cancer immunotherapy , cancer therapy , oncology , cancer , adverse effect
Over a century ago, paths diverged in the treatment of cancer: the well‐traveled path employed cytotoxic chemotherapy drugs, while one of the roads less traveled included immunotherapies. Cancer immunotherapy is now a path to durable responses, however not all patients benefit. Immunotherapy combinations promise responses for a larger proportion of patients, but tolerability can prove to be a barrier. Providing deep, durable responses to more patients requires us to successfully navigate emerging combination tolerability issues.